- Home
- DSP vs FBRX Comparison
DSP vs FBRX Comparison
Compare DSP & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- FBRX
- Stock Information
- Founded
- DSP 1999
- FBRX N/A
- Country
- DSP United States
- FBRX United States
- Employees
- DSP N/A
- FBRX N/A
- Industry
- DSP EDP Services
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- DSP Technology
- FBRX Health Care
- Exchange
- DSP Nasdaq
- FBRX Nasdaq
- Market Cap
- DSP 142.1M
- FBRX 154.5M
- IPO Year
- DSP 2021
- FBRX N/A
- Fundamental
- Price
- DSP $8.16
- FBRX $12.08
- Analyst Decision
- DSP Strong Buy
- FBRX Strong Buy
- Analyst Count
- DSP 9
- FBRX 3
- Target Price
- DSP $20.44
- FBRX $68.00
- AVG Volume (30 Days)
- DSP 309.6K
- FBRX 92.6K
- Earning Date
- DSP 11-11-2025
- FBRX 11-13-2025
- Dividend Yield
- DSP N/A
- FBRX N/A
- EPS Growth
- DSP N/A
- FBRX N/A
- EPS
- DSP 0.13
- FBRX N/A
- Revenue
- DSP $318,471,000.00
- FBRX N/A
- Revenue This Year
- DSP $16.44
- FBRX N/A
- Revenue Next Year
- DSP $15.32
- FBRX N/A
- P/E Ratio
- DSP $61.07
- FBRX N/A
- Revenue Growth
- DSP 30.92
- FBRX N/A
- 52 Week Low
- DSP $8.11
- FBRX $4.11
- 52 Week High
- DSP $26.33
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- DSP 37.14
- FBRX 41.69
- Support Level
- DSP $8.11
- FBRX $13.76
- Resistance Level
- DSP $8.67
- FBRX $14.99
- Average True Range (ATR)
- DSP 0.37
- FBRX 1.22
- MACD
- DSP 0.05
- FBRX -0.41
- Stochastic Oscillator
- DSP 7.69
- FBRX 12.75
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).